<DOC>
	<DOCNO>NCT00217724</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , work different way stop growth cancer cell , either kill cell stop dividing . Nutritional supplement , glutamine , may prevent side effect cause chemotherapy . PURPOSE : This randomized clinical trial study glutamine see well work compare placebo prevent myalgia and/or arthralgia patient receive paclitaxel cancer .</brief_summary>
	<brief_title>Glutamine Preventing Myalgia and/or Arthralgia Patients Who Are Receiving Paclitaxel For Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy glutamine supplementation v placebo , term prevention paclitaxel-induced myalgia and/or arthralgia , patient cancer . Secondary - Compare attenuation myalgia and/or arthralgia patient experience myalgia and/or arthralgia treat regimen . OUTLINE : This randomize , double-blind , crossover , pilot study . Patients randomize 1 2 treatment arm . - Arm I : Beginning day 2 course 1 paclitaxel administration , patient receive oral glutamine three time daily 4 day . - Arm II : Beginning day 2 course 1 paclitaxel administration , patient receive oral placebo three time daily 4 day . Both arm crossover course 2 . In arm , treatment continue absence unacceptable toxicity . After completion study treatment , patient follow 7-10 day . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Arthralgia</mesh_term>
	<mesh_term>Myalgia</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion Criteria . Signed informed patient consent Adult patient ( Age &gt; 18 year old ) neoplastic disorder require paclitaxel part therapy , whether curative palliative intent . Patients must &gt; 2 additional plan course paclitaxel . Patients may outpatient inpatient time enrollment . Patient must myalgias and/or arthralgias recent course ( ) paclitaxel . Paclitaxel must administer 3 hour less infusion . Patients may chronic pain must able differentiate either myalgias arthralgia stable medication regimen pain management . Eastern Cooperative Group ( ECOG ) Performance status score &lt; 3 If consent laboratory portion study participant must normal creatinine phosphokinase within 14 day study entry . The patient , sexually active , must willing agree use approve form birth control . Exclusion criterion . The patient receive another investigational drug within past 30 day . No myalgia arthralgias prior paclitaxel course . The patient uncontrolled ( last 30 day ) , clinically significant confound medical condition rheumatoid disease , fibromyalgia , chronic fatigue syndrome . Also patient viral infection , cold symptom , fever ( &gt; 38 C degree celsius ) influenza . Patients exist neuropathy neurologic disorder would prevent accurately assess onset extent myalgia arthralgia . The patient significant medical intervention last 30 day The patient pregnant lactating . Patients unable take oral medication medical condition might inhibit ability absorb protein gastrointestinal tract . Patients unwilling abstain additional protein supplement kind obtain `` normal '' dietary intake . Patients required take nonsteroidal antiinflammatory agent ( NSAIDS ) , antioxidant vitamin , unable unwilling abstain 1 week prior glutamine/placebo therapy . Patients metabolic error abnormality protein metabolism . Patients history blood urea nitrogen level &gt; 2 time normal normal serum creatinine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>pain</keyword>
</DOC>